Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

GLP-1 RA use is associated with better graft and patient survival among kidney transplant recipients with diabetes.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

Preoperative glucagon-like peptide-1 receptor agonist use is not associated with short-term postoperative aspiration pneumonia.

"This finding suggests that it may be beneficial to reassess the preoperative withholding guidelines for GLP-1 RAs." HealthDay News — Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 ...

Three studies attempting to tease out the potential effects of glucagon-like peptide 1 receptor agonists (GLP-1 RA) taken before or during pregnancy were presented at the annual meeting of the ...

Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's ... ZLDPF), Terns Pharmaceuticals (TERN) and Structure Therapeutics (GPCR).

Adults aged 66 years or older with T2D initiating treatment with a GLP-1 RA were propensity score-matched to those initiating treatment with an SGLT-2i (14,665 matched pairs) or a DPP-4i (13,711 ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with type 2 diabetes is linked to a reduced risk of developing certain hematologic cancers compared to insulin and metformin.

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...